The Business Behind...
Health Care: Drugs
Santarus Inc. (SNTS: NASDAQ)
$22.22 0.12 | 0.54%
05/21/13 - 03:20 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with SNTS
- Portfolio NameUser Type
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorBreakout Stocks Of The Week...
- UserRogers BioMed
- ContributorStocks At New 52-Week Highs...
- UserJust Learning ao926
- UserJust Learning
- ContributorDollar Store
- Userbetterlatethannever
Latest SNTS Headlines from TheStreet
- Dow Closes at Record High 03.05.13 | 04:03 pm
- Cramer's 'Mad Money' Recap: The Bullish Facts 01.17.13 | 08:01 pm
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
- Top Insider Trades: LMCA, ST, SNTS, BEAV 12.20.12 | 01:12 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 5 Under-$10 Stocks Set to Trade Higher in November 11.08.12 | 01:11 pm
- Santarus Inc. Stock Upgraded (SNTS) 08.27.12 | 05:08 am
- Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.07.12 | 09:08 pm
- Santarus Reaches New 52-Week High (SNTS) 06.12.12 | 04:06 pm
- Santarus Stock Falls On Unusually High Volume (SNTS) 05.30.12 | 04:05 pm
Press Releases for SNTS
- Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study - Business Wire 03.18.13 | 07:03 am
- Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes - Business Wire 03.06.13 | 07:03 am
- Santarus Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.04.13 | 04:03 pm
- Santarus To Present At March Investment Conferences - Business Wire 02.27.13 | 07:02 am
- Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4 - Business Wire 02.19.13 | 07:02 am
- Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets - Business Wire 02.14.13 | 07:02 am
- Santarus To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study - Business Wire 01.23.13 | 07:01 am
- Santarus Receives FDA Approval Of UCERIS (Budesonide) For The Induction Of Remission In Patients With Active, Mild To Moderate Ulcerative Colitis - Business Wire 01.14.13 | 07:01 pm
- Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association - Business Wire 11.13.12 | 07:11 am
Partner Headlines for SNTS
- IBD 50 Stocks Delivering Strong Earnings, Sales Gains - Investor's Business Daily 05.17.13 | 06:05 pm
- Earnings News Drags On Futures; Whole Foods Market Bolts Higher - Investor's Business Daily 05.08.13 | 09:05 am
- Stocks Build On Q1 Strength; CommVault, MercadoLibre Spike - Investor's Business Daily 05.07.13 | 10:05 am
- Futures Aim Moderately Higher; MercadoLibre, Nationstar Rising - Investor's Business Daily 05.07.13 | 09:05 am
- Santarus Earnings Trounce Estimates; Stock Hits High - Investor's Business Daily 05.06.13 | 05:05 pm
- Santarus Earnings: Here’s Why Investors are Happy Now - Wall St. Cheat Sheet 05.06.13 | 06:05 am
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
